Detalles de la búsqueda
1.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat
; 201(3): 409-415, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480384
2.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484305
3.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296894
4.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Invest New Drugs
; 39(1): 217-225, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32833136
5.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1229-1236, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33891194
6.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 27(11): 1793, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36166110
7.
[Development of a Drug Cost Calculation Tool for Breast Cancer Therapy].
Gan To Kagaku Ryoho
; 42(7): 841-5, 2015 Jul.
Artículo
en Japonés
| MEDLINE | ID: mdl-26197746
8.
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Cancer Med
; 12(17): 17718-17730, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37525895
9.
[High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
Gan To Kagaku Ryoho
; 39(3): 395-8, 2012 Mar.
Artículo
en Japonés
| MEDLINE | ID: mdl-22421766
10.
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.
BMC Cancer
; 11: 118, 2011 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-21453503
11.
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Breast Cancer
; 28(1): 145-160, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32715420
12.
A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Int J Clin Oncol
; 15(6): 615-20, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20473628
13.
Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report.
Anticancer Res
; 40(11): 6465-6471, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109585
14.
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Breast Cancer
; 27(3): 389-398, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31811519
15.
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Breast Cancer
; 25(4): 438-446, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435730
16.
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Curr Med Res Opin
; 34(1): 49-54, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29095648
17.
[Clinical implementation of the immunohistochemical intrinsic subtypes of breast cancer].
Nihon Rinsho
; 70 Suppl 7: 232-7, 2012 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-23350398
18.
Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Breast Cancer
; 22(2): 129-34, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23543399
19.
Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
J Clin Pathol
; 68(5): 356-61, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25673730
20.
Considerable multiple esophageal carcinoma. Implications of a new clinical entity.
Hepatogastroenterology
; 51(60): 1713-6, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15532811